Simulations Plus Inc
NASDAQ:SLP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Simulations Plus Inc
Accrued Liabilities
Simulations Plus Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Simulations Plus Inc
NASDAQ:SLP
|
Accrued Liabilities
$6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
12%
|
CAGR 10-Years
28%
|
|
|
Veeva Systems Inc
NYSE:VEEV
|
Accrued Liabilities
$103.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
16%
|
|
|
Inspire Medical Systems Inc
NYSE:INSP
|
Accrued Liabilities
$57m
|
CAGR 3-Years
18%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Doximity Inc
NYSE:DOCS
|
Accrued Liabilities
$27.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Omnicell Inc
NASDAQ:OMCL
|
Accrued Liabilities
$246.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
14%
|
CAGR 10-Years
21%
|
|
|
W
|
Waystar Holding Corp
NASDAQ:WAY
|
Accrued Liabilities
$64.1m
|
CAGR 3-Years
27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Simulations Plus Inc
Glance View
Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.
See Also
What is Simulations Plus Inc's Accrued Liabilities?
Accrued Liabilities
6m
USD
Based on the financial report for Feb 28, 2026, Simulations Plus Inc's Accrued Liabilities amounts to 6m USD.
What is Simulations Plus Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
28%
Over the last year, the Accrued Liabilities growth was -2%. The average annual Accrued Liabilities growth rates for Simulations Plus Inc have been 19% over the past three years , 12% over the past five years , and 28% over the past ten years .
